BioCentury
ARTICLE | Clinical News

RHB-104: Interim Phase IIa data

April 11, 2016 7:00 AM UTC

Interim data from the open-label, dose-escalation, Israeli Phase IIa CEASE-MS trial in 18 patients with RRMS showed that twice-daily oral RHB-104 as add-on to Avonex interferon beta-1a led to no “clinically significant” change in total CUA lesions from baseline to week 24, which RedHill said is supportive of a stable disease state. The company said there was 1 single active T1 post-gadolinium lesion and that CUAs “were almost entirely driven by changes in T2 lesions.” CUAs are defined as active lesions on T1 post-gadolinium, T2 sequences or both, avoiding double counting. A T2 lesion was defined as a new or enlarging lesion or a lesion reappearing at a site of previous lesion resolution. ...